HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…

By STAT News · May 21, 2026 · via STAT News
STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News →

Tags
pipelineformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
PipelineFiercePharma ↗
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
May 25, 2026
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
PipelineFiercePharma ↗
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
May 24, 2026
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
PipelineFiercePharma ↗
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …
May 23, 2026